BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Approves Paradigm Spine, LLC's Cost-Saving Coflex Spinal Stenosis Treatment


10/18/2012 8:44:52 AM

Paradigm Spine wins FDA approval for the 1st device that treats moderate to severe spinal stenosis with or without back pain, with study results finding that the device preserves motion and saves costs compared with traditional pedicle screw fusion. Paradigm Spine won FDA approval for its Coflex spinal stenosis treatment system, the 1st such device to treat moderate to severe cases of spinal stenosis that may present with or without back pain. Paradigm calls the Coflex device the "the 1st and only motion-preserving alternative to fusion for the treatment of moderate to severe spinal stenosis." The approval was based on clinical results from the company's investigational device exemption study that compared the Coflex device to pedicle screw fusion, the current standard of care. The results showed that Coflex met or beat fusion in all major primary and secondary endpoints, Paradigm reported. Coflex patients spent 40% less time in the hospital and surgeries were performed 36% faster, according to the study. In addition, 85.5% of Coflex patients reported improvements in pain and function after 2 years, compared with 76.7% of patients who received the current standard of care.

Read at MassDevice

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES